These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 35584372

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Brain insulin resistance: role in neurodegenerative disease and potential for targeting.
    Hölscher C.
    Expert Opin Investig Drugs; 2020 Apr; 29(4):333-348. PubMed ID: 32175781
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
    Feng P, Zhang X, Li D, Ji C, Yuan Z, Wang R, Xue G, Li G, Hölscher C.
    Neuropharmacology; 2018 May 01; 133():385-394. PubMed ID: 29462693
    [Abstract] [Full Text] [Related]

  • 7. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
    Hölscher C.
    Neuropharmacology; 2018 Jul 01; 136(Pt B):251-259. PubMed ID: 29402504
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
    Yang B, Gelfanov VM, El K, Chen A, Rohlfs R, DuBois B, Kruse Hansen AM, Perez-Tilve D, Knerr PJ, D'Alessio D, Campbell JE, Douros JD, Finan B.
    Mol Metab; 2022 Dec 01; 66():101638. PubMed ID: 36400403
    [Abstract] [Full Text] [Related]

  • 11. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
    Al-Sabah S, Al-Fulaij M, Shaaban G, Ahmed HA, Mann RJ, Donnelly D, Bünemann M, Krasel C.
    PLoS One; 2014 Dec 01; 9(9):e106890. PubMed ID: 25191754
    [Abstract] [Full Text] [Related]

  • 12. GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.
    Mayendraraj A, Rosenkilde MM, Gasbjerg LS.
    Peptides; 2022 May 01; 151():170749. PubMed ID: 35065096
    [Abstract] [Full Text] [Related]

  • 13. Body weight lowering effect of glucose-dependent insulinotropic polypeptide and glucagon-like peptide receptor agonists is more efficient in RAMP1/3 KO than in WT mice.
    Leuthardt AS, Boyle CN, Raun K, Lutz TA, John LM, Le Foll C.
    Eur J Pharmacol; 2023 Sep 15; 955():175912. PubMed ID: 37454968
    [Abstract] [Full Text] [Related]

  • 14. Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease.
    Glotfelty EJ, Olson L, Karlsson TE, Li Y, Greig NH.
    Expert Opin Investig Drugs; 2020 Jun 15; 29(6):595-602. PubMed ID: 32412796
    [Abstract] [Full Text] [Related]

  • 15. The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review.
    Mathiesen DS, Bagger JI, Bergmann NC, Lund A, Christensen MB, Vilsbøll T, Knop FK.
    Int J Mol Sci; 2019 Aug 22; 20(17):. PubMed ID: 31443356
    [Abstract] [Full Text] [Related]

  • 16. GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy.
    Lafferty RA, Flatt PR, Irwin N.
    Expert Opin Pharmacother; 2023 Apr 22; 24(5):587-597. PubMed ID: 36927378
    [Abstract] [Full Text] [Related]

  • 17. Targeting glucose-dependent insulinotropic polypeptide receptor for neurodegenerative disorders.
    Verma MK, Goel R, Krishnadas N, Nemmani KVS.
    Expert Opin Ther Targets; 2018 Jul 22; 22(7):615-628. PubMed ID: 29911915
    [Abstract] [Full Text] [Related]

  • 18. A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat.
    Han L, Hölscher C, Xue GF, Li G, Li D.
    Neuroreport; 2016 Jan 06; 27(1):23-32. PubMed ID: 26555034
    [Abstract] [Full Text] [Related]

  • 19. Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration.
    Kopp KO, Li Y, Glotfelty EJ, Tweedie D, Greig NH.
    Biomolecules; 2024 Jul 19; 14(7):. PubMed ID: 39062586
    [Abstract] [Full Text] [Related]

  • 20. Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders.
    Hölscher C.
    Br J Pharmacol; 2022 Feb 19; 179(4):695-714. PubMed ID: 33900631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.